Neuronano AB

It is no coincidence that our research and development is based in Medicon Village, Lund. Together with 180 other companies, Medicon Village forms the largest science park in Scandinavia, focused on Life Science. Medicon Village is part of Medicon Valley, one of Europe’s top Life Science clusters, linking southern Sweden and eastern Denmark. The region combines Sweden’s strength in medtech with Denmark’s pharmaceutical expertise, offering easy access to international markets. With 12 universities and world-class research institutes, Medicon Valley provides a vibrant innovative atmosphere with unique business opportunities to leverage advanced research and skilled talent.

Conventional technology in Deep Brain Stimulation (DBS) utilizes leads with an approximate diameter of 1.3 mm. This is 10-100 times the size of a typical brain cell, affecting a significant amount of tissue during implantation. Neuronano’s solution is to use microelectrodes, with a similar diameter as the typical neuron, which enables a smooth implantation with minimal damage to the tissue to be stimulated. How do we get adequate stimulation at the correct spot, you may ask? By using a cluster of microelectrodes spread in the target area, we can select the microelectrode(s) closest to the optimal position for maximal symptom relief. Read more about our ongoing research at neuronano.se “The future is near."

"The goal of the next generation of implant technology is to provide more effective and personalized treatment and minimize risks." Jens Schouenborg Thanks to everyone who joined us and listened to the discussion "Healthy, Smart, and Happy – Brain Research and Ethics," organized by Smer, in Almedalen last week. A very important conversation about the future. Read the article and watch the full seminar: https://lnkd.in/gX8rZVaX (in swedish)

Meet Niclas Lindqvist, one of our scientists who are working on development of the DBS-probe. His work mainly focuses on the gelatin, which is a part of the probe, and it involves performing tests and experiments to optimize the function of the DBS-probe. Something that really motivates Niclas in his work is the pure technical work, he enjoys to be close to the action in the laboratory, where things happen. Read the full interview with Niclas on https://lnkd.in/dqAbdBUg

At Neuronano, our mission is to innovate, patent, develop, and commercialize advanced electrodes designed for implantation in the brain. These electrodes aim to offer alternatives or complements to pharmacological treatments for conditions such as Parkinson's disease. Our research is progressing steadily, and we are pleased with the positive results from our testing thus far. Stay informed about our ongoing research by visiting neuronano.se.

Neuronano’s technology for Deep Brain Stimulation (DBS) is a novel invention in several important aspects compared to today’s treatments. The DBS treatment used today is based on technology primarily developed in the 1980s and 90s. Neuronano’s innovative technology enables the stimulation of nerve cells in the brain with much greater precision to produce the best result. This also mean fewer side effects and better effectiveness which result in a considerably higher quality of life. Read more about our research at Neuronano.se

Patient safety is Neuronano’s primary focus, every detail of our technology is carefully considered. We eliminate risks by only using tissue-friendly materials which meet all applicable regulatory requirements and innovative constructions which permit a gentle neurosurgical implantation technique. You can read more about our Research and Development at https://lnkd.in/gtm45A7

Neuronano and Prof. Jens Schouenborg discuss the future of brain research in today's news on Vetenskapsradion, Sveriges Radio, ’Brain chips in humans have become a reality - this is how they should be used.' Listen here: https://lnkd.in/dD3rWMqB

On January 29th, Elon Musk announced that Neuralink had successfully implanted its wireless brain chip into a human. The goal is to help paralyzed people to walk again, but they are also talking about human/AI symbiosis, something Musk describes as "species-level important".   "It's nice to see that this kind of research gets attention, but it's difficult to make a justified statement about Elon Musk’s progress at this point. The major challenge for Neuralink lies in obtaining stable recordings over an extended duration. This is partly due to the movement of the brain within the skull, which can result in unstable electrode positions in the brain." Dr Jens Schouenborg, Neuronano   Follow us to keep up with our research 🧠

Neuronano is pioneering in highly specific Deep Brain Stimulation (DBS) therapy. We do this by optimizing the implantation process in addition to utilizing a controlled array of super thin electrodes that can be individually controlled. Neuronano’s DBS offers personalized therapy for Parkinson’s, tailored to the unique needs of each patient, with limited side effects. Normally, pharmaceutical care for Parkinson's disease, employing medications like levodopa and dopamine agonists, offers symptom relief but poses risks due to potential side effects. Common adverse reactions include dyskinesias, nausea, hallucinin compations, and motor fluctuations. Prolonged use, especially of levodopa, may lead to cognitive issues. Read more about our research at https://lnkd.in/gtm45A7